Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04803201 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 170 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease(CIRCULATE-US) | recruiting | Phase 2 / Phase 3 | 1,912 | NRG OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT05286814 | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07292298 | Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates | recruiting | Phase 2 | 44 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06992258 | A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer(FRUITION) | recruiting | Phase 2 | 120 | Criterium, Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07071961 | Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] | recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07474727 | A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | recruiting | Phase 2 | 180 | Multitude Therapeutics Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789210 | A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases(NEORAF) | recruiting | Phase 2 | 25 | Zhejiang UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07790510 | HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 180 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06617858 | Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment | recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03190941 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | recruiting | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03965234 | Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases | recruiting | Phase 1 / Phase 2 | 99 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04205968 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | recruiting | Phase 2 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05254327 | Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 | recruiting | Phase 2 | 118 | University of NebraskaOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07235293 | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | recruiting | Phase 2 | 90 | Kahr Bio Australia Pty LtdINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06728072 | Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer | recruiting | Phase 2 | 97 | Virginia Commonwealth UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06792695 | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer(CANTOR) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 12 | Aug 18, 2026 | clinicaltrials |
| NCT07735624 | RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer(RECTIFY-1) | recruiting | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07425054 | ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer(CHART-AC) | recruiting | Phase 2 | 33 | Jennifer DorthOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | recruiting | Phase 1 / Phase 2 | 240 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07277322 | Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | recruiting | Phase 1 / Phase 2 | 24 | Dan FengOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT07162714 | SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer(STAR) | recruiting | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06949098 | Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06949111 | Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） | recruiting | Phase 2 | 128 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 370 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04912765 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | recruiting | Phase 2 | 60 | National Cancer Centre, SingaporeOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | recruiting | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT07736495 | Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis | recruiting | Phase 2 / Phase 3 | 50 | Ain Shams UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT05024097 | A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.(PANTHER) | recruiting | Phase 2 | 43 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06321081 | ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | recruiting | Phase 2 | 60 | Beijing HospitalOTHER_GOV | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06493019 | Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | recruiting | Phase 2 | 23 | Dustin DemingOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | recruiting | Phase 2 | 36 | Tiago Biachi de CastriaOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07411599 | Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial") | recruiting | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07104604 | Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement | recruiting | Phase 2 | 51 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07724223 | Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC | recruiting | Phase 2 | 46 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07133750 | PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | recruiting | Phase 2 | 100 | Biotheus Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07718490 | Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer | recruiting | Phase 2 | 43 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07281768 | Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 66 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06907342 | Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)(COSENSE-1) | recruiting | Phase 2 | 148 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2026source: clinicaltrials